Synlogic gets grant for genetically engineered bacteria for treating phenylketonuria
Pharmaceutical Technology
MARCH 28, 2024
Discover how Synlogic Inc's patented genetically programmed microorganisms can modulate and treat diseases. Learn about the innovative method for producing pharmaceutical compositions using non-pathogenic bacteria to metabolize phenylalanine. Explore the potential applications in gut microbiome and tumor environments.
Let's personalize your content